Aperturetx
2 known investors
Find your way into Aperturetx
987 people in our graph share verified history with the Aperturetx team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Martin Jacko · together at Stanford University (overlapped)
×8knows the team · via Stanford University
×3knows the team · via Columbia University
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging. It targets shared drivers of both familial and sporadic disease, often related to neuroinflammation.
Founders & leadership
MJ
Martin JackoinFounder & CEOMartin Jacko is founder and CEO of Aperture Therapeutics, which uses machine learning to identify protective gene variants and develop oligonucleotide therapeutics for neurodegenerative diseases. He previously held R&D and business development roles at BridgeBio Pharma and Serotiny (acquired by Johnson & Johnson), and completed a postdoctoral fellowship at Stanford University on high-throughput screening platforms for neuronal circuits, following a Ph.D. from Columbia University in molecular neurobiology.
Investors · 2
Frequently asked questions
- What does Aperturetx do?
- Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging. It targets shared drivers of both familial and sporadic disease, often related to neuroinflammation.
- Who founded Aperturetx?
- Aperturetx was founded by Martin Jacko.
- Who are Aperturetx's investors?
- Aperturetx's investors include age1, XEIA Venture Partners.